Blackstone Inc
XERS icon

Blackstone Inc’s Xeris Biopharma Holdings XERS Stock Holding History

Blackstone Inc’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-390,975
Closed -$762K – 164
2020
Q1 		$762K Sell
390,975
-59,025
-13% -$254K 0.01% 73
2019
Q4 		$3.17M Buy
+450,000
New +$3.72M 0.02% 47

Other funds holding XERS

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Blackstone Inc's XERS Position: Q2 2020 in Review

Blackstone Inc sold out of Xeris Biopharma Holdings (XERS) in Q2 2020, closing a stake of 390,975 shares — an estimated $762K sold.

Blackstone Inc first reported a position in XERS in Q4 2019 and held it in 2 quarters. The position peaked at $3.17M in Q4 2019. 86 funds tracked by Wall St. Rank hold XERS as of Q2 2020.

  • Blackstone Inc reported no remaining Xeris Biopharma Holdings position as of Q2 2020 after selling out during the quarter.
  • Blackstone Inc sold 390,975 Xeris Biopharma Holdings shares in Q2 2020, an estimated $762K.
  • Blackstone Inc first reported a position in Xeris Biopharma Holdings in Q4 2019 and held it in 2 quarters.
  • Blackstone Inc's Xeris Biopharma Holdings position peaked at $3.17M in Q4 2019.
  • 86 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2020.

Based on Blackstone Inc's 13F filing for Q2 2020, filed 14 Aug 2020.